Table 1.
Patient demographics including details of localised and systemic treatment received
| Number (%) | Mean | Range | Interquartile range | ||
|---|---|---|---|---|---|
| Male | 51 (72.9) | ||||
| Female | 19 (27.1) | ||||
| Age | 63 | 32–87 | 54–73 | ||
| BRAF V600 status | Mutant | 46 (65.7) | |||
| Wild-type | 24 (34.3) | ||||
| At point of Diagnosis | Localised | 49 (70.0) | |||
| Metastatic disease | 21 (30.0) | ||||
| Brain metastases | 11 (15.7) | ||||
| Time from diagnosis to development of brain metastases (months) | 29.6 | 0–148 | 4.2–39.2 | ||
| At point of diagnosis with metastatic melanoma | Brain metastases | 37 (52.9) | |||
| No brain metastases | 33 (47.1) | ||||
| Time from metastatic diagnosis to development of brain metastases (months) | 3.5 | 0–22.7 | 0–4.5 | ||
| Localised treatment | Total | 51 (72.9) | |||
| Surgery only | 7 (10.0) | ||||
| SRS only | 33 (47.1) | ||||
| Surgery and SRS | 11 (15.7) | ||||
| First line systemic treatment | Total | 69 (98.6) | |||
| BRAF inhibitor | 15 (21.4) | ||||
| BRAF + MEK inhibitors | 19 (27.1) | ||||
| Ipilimumab | 7 (10.0) | ||||
| Anti-PD-1 | 21 (30.0) | ||||
| Dual immunotherapy | 5 (7.1) | ||||
| No localised treatment | 19 (27.1) | ||||